Key Highlights
- Strategic partnership between Owkin and Proscia to advance AI-enabled MSI testing for colorectal cancer (CRC).
- Integration of Owkin’s MSIntuit CRC v2 with Proscia’s Concentriq software to enhance precision medicine capabilities.
- MSI biomarker testing aids CRC treatment decisions, ensuring patients receive optimal therapies.
- Partnership aligns with universal screening guidelines to address current testing challenges.
Source: Business Wire
Notable Quotes
- “While MSI screening helps ensure that each patient receives the best course of treatment, it puts added burden on pathologists and laboratories. We are thrilled to partner with Proscia and execute on our shared vision of harnessing the power of AI to transform medical research and diagnosis.” — Dr. Thomas Clozel, CEO at Owkin
- “Our shared focus on advancing pathology from drug discovery to diagnostics uniquely positions us to unlock the potential of AI on novel therapies and treatment decisions.” — David West, CEO at Proscia
SoHC's Take
This partnership marks a significant step in the evolution of precision medicine. By integrating Owkin’s advanced MSI testing technology with Proscia’s enterprise pathology platform, the collaboration aims to address the longstanding challenges in MSI screening, such as cost, accessibility, and diagnostic accuracy. Given colorectal cancer’s global impact, particularly as the second deadliest cancer worldwide, this innovation could greatly expand access to crucial diagnostics, ensuring timely and accurate treatment decisions. The strategic alignment of Owkin and Proscia underscores a shared vision to leverage AI for transformative advancements in healthcare, signaling a promising future for personalized medicine.
